{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,27]],"date-time":"2026-07-27T13:34:48Z","timestamp":1785159288439,"version":"3.55.0"},"reference-count":203,"publisher":"Elsevier BV","issue":"6","license":[{"start":{"date-parts":[[2008,12,1]],"date-time":"2008-12-01T00:00:00Z","timestamp":1228089600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Molecular Aspects of Medicine"],"published-print":{"date-parts":[[2008,12]]},"DOI":"10.1016\/j.mam.2008.04.001","type":"journal-article","created":{"date-parts":[[2008,5,4]],"date-time":"2008-05-04T05:09:38Z","timestamp":1209877778000},"page":"433-452","source":"Crossref","is-referenced-by-count":137,"title":["Vitamin D analogs: Therapeutic applications and mechanisms for selectivity"],"prefix":"10.1016","volume":"29","author":[{"given":"Alex J.","family":"Brown","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Eduardo","family":"Slatopolsky","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.mam.2008.04.001_bib1","first-page":"2534","article-title":"Antitumor effect of 22-oxa-calcitriol, a noncalcemic analogue of calcitriol, in athymic mice implanted with human breast carcinoma and its synergism with tamoxifen","volume":"53","author":"Abe-Hashimoto","year":"1993","journal-title":"Cancer Res."},{"key":"10.1016\/j.mam.2008.04.001_bib2","doi-asserted-by":"crossref","first-page":"4990","DOI":"10.1073\/pnas.78.8.4990","article-title":"Differentiation of mouse myeloid leukemia cells induced by 1 alpha,25-dihydroxyvitamin D3","volume":"78","author":"Abe","year":"1981","journal-title":"Proc. Natl. Acad. Sci. U.S.A."},{"key":"10.1016\/j.mam.2008.04.001_bib3","doi-asserted-by":"crossref","first-page":"21","DOI":"10.3177\/jnsv.36.21","article-title":"Prevention of immunological disorders in MRL\/l mice by a new synthetic analogue of vitamin D3: 22-oxa-1 alpha,25-dihydroxyvitamin D3","volume":"36","author":"Abe","year":"1990","journal-title":"J. Nutr. Sci. Vitaminol."},{"key":"10.1016\/j.mam.2008.04.001_bib4","doi-asserted-by":"crossref","first-page":"832","DOI":"10.1210\/endo-129-2-832","article-title":"A novel vitamin D3 analog, 22-oxa-1,25-dihydroxyvitamin D3, inhibits the growth of human breast cancer in vitro and in vivo without causing hypercalcemia","volume":"129","author":"Abe","year":"1991","journal-title":"Endocrinology"},{"key":"10.1016\/j.mam.2008.04.001_bib5","doi-asserted-by":"crossref","first-page":"461","DOI":"10.1016\/j.jsbmb.2004.03.016","article-title":"Response element binding proteins and intracellular vitamin D binding proteins: novel regulators of vitamin D trafficking, action and metabolism","author":"Adams","year":"2004","journal-title":"J. Steroid Biochem. Mol. Biol."},{"key":"10.1016\/j.mam.2008.04.001_bib6","doi-asserted-by":"crossref","first-page":"80","DOI":"10.1038\/ncpendmet0716","article-title":"Unexpected actions of vitamin D: new perspectives on the regulation of innate and adaptive immunity","volume":"4","author":"Adams","year":"2008","journal-title":"Nat. Clin. Pract. Endocrinol. Metab."},{"key":"10.1016\/j.mam.2008.04.001_bib7","doi-asserted-by":"crossref","first-page":"115","DOI":"10.1016\/j.cellimm.2005.04.013","article-title":"Intervention in autoimmunity: the potential of vitamin D receptor agonists","volume":"233","author":"Adorini","year":"2005","journal-title":"Cell Immunol."},{"key":"10.1016\/j.mam.2008.04.001_bib8","doi-asserted-by":"crossref","first-page":"34","DOI":"10.1016\/j.imlet.2005.06.017","article-title":"Prevention of chronic allograft rejection by Vitamin D receptor agonists","volume":"100","author":"Adorini","year":"2005","journal-title":"Immunol. Lett."},{"key":"10.1016\/j.mam.2008.04.001_bib9","doi-asserted-by":"crossref","first-page":"689","DOI":"10.1016\/j.jsbmb.2006.12.065","article-title":"Inhibition of prostate growth and inflammation by the vitamin D receptor agonist BXL-628 (elocalcitol)","volume":"103","author":"Adorini","year":"2007","journal-title":"J. Steroid Biochem. Mol. Biol."},{"key":"10.1016\/j.mam.2008.04.001_bib10","doi-asserted-by":"crossref","first-page":"317","DOI":"10.1007\/BF02050422","article-title":"Vitamin D3 analog, EB1089, inhibits growth of subcutaneous xenografts of the human colon cancer cell line, LoVo, in a nude mouse model","volume":"40","author":"Akhter","year":"1997","journal-title":"Diseases Colon Rectum"},{"key":"10.1016\/j.mam.2008.04.001_bib11","doi-asserted-by":"crossref","first-page":"480","DOI":"10.1111\/j.1774-9987.2004.00191.x","article-title":"Dose-response study of 22-oxacalcitriol in patients with secondary hyperparathyroidism","volume":"8","author":"Akizawa","year":"2004","journal-title":"Ther. Apher. Dial."},{"issue":"Suppl. 10","key":"10.1016\/j.mam.2008.04.001_bib12","doi-asserted-by":"crossref","first-page":"28","DOI":"10.1093\/ndt\/17.suppl_10.28","article-title":"Long-term effect of 1,25-dihydroxy-22-oxavitamin D(3) on secondary hyperparathyroidism in haemodialysis patients. One-year administration study","volume":"17","author":"Akizawa","year":"2002","journal-title":"Nephrol. Dial Transplant."},{"key":"10.1016\/j.mam.2008.04.001_bib13","doi-asserted-by":"crossref","first-page":"1357","DOI":"10.1001\/archopht.122.9.1357","article-title":"Effectiveness of vitamin D analogues in treating large tumors and during prolonged use in murine retinoblastoma models","volume":"122","author":"Albert","year":"2004","journal-title":"Arch. Ophthalmol."},{"key":"10.1016\/j.mam.2008.04.001_bib14","doi-asserted-by":"crossref","first-page":"401","DOI":"10.1016\/0002-9343(88)90259-8","article-title":"Calcitriol in the treatment of postmenopausal osteoporosis","volume":"84","author":"Aloia","year":"1988","journal-title":"Am. J. Med."},{"key":"10.1016\/j.mam.2008.04.001_bib15","first-page":"1653","article-title":"1 alpha,25-Dihydroxy-16-ene-23-yne-26,27-hexafluorocholecalciferol (Ro24-5531), a new deltanoid (vitamin D analogue) for prevention of breast cancer in the rat","volume":"54","author":"Anzano","year":"1994","journal-title":"Cancer Res."},{"key":"10.1016\/j.mam.2008.04.001_bib16","doi-asserted-by":"crossref","unstructured":"Aparna, R., Subhashini, J., Roy, K.R., Reddy, G.S., Robinson, M., Uskokovic, M.R., Venkateswara Reddy, G., Reddanna, P., 2008. Selective inhibition of cyclooxygenase-2 (COX-2) by 1alpha,25-dihydroxy-16-ene-23-yne-vitamin D(3), a less calcemic vitamin D analog. J. Cell Biochem.","DOI":"10.1002\/jcb.21749"},{"key":"10.1016\/j.mam.2008.04.001_bib17","first-page":"191","article-title":"The relation of solar radiation to cancer mortality in North America","volume":"1","author":"Apperly","year":"1941","journal-title":"Cancer Res."},{"key":"10.1016\/j.mam.2008.04.001_bib18","doi-asserted-by":"crossref","first-page":"274","DOI":"10.1046\/j.1365-2133.1999.02975.x","article-title":"Topical maxacalcitol for the treatment of psoriasis vulgaris: a placebo-controlled, double-blind, dose-finding study with active comparator","volume":"141","author":"Barker","year":"1999","journal-title":"Br. J. Dermatol."},{"key":"10.1016\/j.mam.2008.04.001_bib19","doi-asserted-by":"crossref","first-page":"669","DOI":"10.1200\/JCO.2006.06.8197","article-title":"Double-blinded randomized study of high-dose calcitriol plus docetaxel compared with placebo plus docetaxel in androgen-independent prostate cancer: a report from the ASCENT Investigators","volume":"25","author":"Beer","year":"2007","journal-title":"J. Clin. Oncol."},{"key":"10.1016\/j.mam.2008.04.001_bib20","doi-asserted-by":"crossref","first-page":"693","DOI":"10.1111\/1523-1747.ep12324474","article-title":"22-Oxa calcitriol is a less potent regulator of keratinocyte proliferation and differentiation due to decreased cellular uptake and enhanced catabolism","volume":"105","author":"Bikle","year":"1995","journal-title":"J. Invest. Dermatol."},{"key":"10.1016\/j.mam.2008.04.001_bib21","doi-asserted-by":"crossref","first-page":"240","DOI":"10.1111\/j.1600-0773.1993.tb01643.x","article-title":"Comparison of calcipotriol with selected metabolites and analogues of vitamin D3: effects on cell growth regulation in vitro and calcium metabolism in vivo","volume":"72","author":"Binderup","year":"1993","journal-title":"Pharmacol. Toxicol."},{"key":"10.1016\/j.mam.2008.04.001_bib22","doi-asserted-by":"crossref","first-page":"889","DOI":"10.1016\/0006-2952(88)90177-3","article-title":"Effects of a novel vitamin D analogue MC903 on cell proliferation and differentiation in vitro and on calcium metabolism in vivo","volume":"37","author":"Binderup","year":"1988","journal-title":"Biochem. Pharmacol."},{"key":"10.1016\/j.mam.2008.04.001_bib23","first-page":"401","article-title":"Origin of the use of calcipotriol in psoriasis treatment","volume":"3","author":"Binderup","year":"1992","journal-title":"Rev. Contemporary Pharmacotherapy"},{"key":"10.1016\/j.mam.2008.04.001_bib24","doi-asserted-by":"crossref","first-page":"264","DOI":"10.1186\/1471-2407-6-264","article-title":"Solar ultraviolet-B exposure and cancer incidence and mortality in the United States, 1993\u20132002","volume":"6","author":"Boscoe","year":"2006","journal-title":"BMC Cancer"},{"key":"10.1016\/j.mam.2008.04.001_bib25","doi-asserted-by":"crossref","first-page":"701","DOI":"10.1016\/0140-6736(91)90280-3","article-title":"Topical calcipotriol treatment in advanced breast cancer [published erratum appears in Lancet 1991 Jun 29;337(8757):1618] [see comments]","volume":"337","author":"Bower","year":"1991","journal-title":"Lancet"},{"key":"10.1016\/j.mam.2008.04.001_bib26","doi-asserted-by":"crossref","first-page":"759","DOI":"10.1016\/0006-291X(92)92266-Z","article-title":"Metabolism of 22-oxacalcitriol by a vitamin D-inducible pathway in cultured parathyroid cells","volume":"189","author":"Brown","year":"1992","journal-title":"Biochem. Biophys. Res. Commun."},{"key":"10.1016\/j.mam.2008.04.001_bib27","doi-asserted-by":"crossref","first-page":"1158","DOI":"10.1210\/en.133.3.1158","article-title":"The mechanism for the disparate actions of calcitriol and 22-oxacalcitriol in the intestine","volume":"133","author":"Brown","year":"1993","journal-title":"Endocrinology"},{"issue":"Suppl. 29","key":"10.1016\/j.mam.2008.04.001_bib28","first-page":"S22","article-title":"New active analogues of vitamin D with low calcemic activity","volume":"29","author":"Brown","year":"1990","journal-title":"Kidney Int."},{"key":"10.1016\/j.mam.2008.04.001_bib29","doi-asserted-by":"crossref","first-page":"2088","DOI":"10.1681\/ASN.V11112088","article-title":"The calcemic activity of 19-nor-1,25(OH)2 D2 decreases with duration of treatment","volume":"11","author":"Brown","year":"2000","journal-title":"J. Am. Soc. Nephrol."},{"key":"10.1016\/j.mam.2008.04.001_bib30","doi-asserted-by":"crossref","first-page":"728","DOI":"10.1172\/JCI114229","article-title":"The noncalcemic analogue of vitamin D, 22-oxacalcitriol, suppresses parathyroid hormone synthesis and secretion","volume":"84","author":"Brown","year":"1989","journal-title":"J. Clin. Invest."},{"key":"10.1016\/j.mam.2008.04.001_bib31","doi-asserted-by":"crossref","first-page":"569","DOI":"10.1002\/jcb.20553","article-title":"Isolation and identification of 1alpha-hydroxy-3-epi-vitamin D3, a potent suppressor of parathyroid hormone secretion","volume":"96","author":"Brown","year":"2005","journal-title":"J. Cell Biochem."},{"key":"10.1016\/j.mam.2008.04.001_bib32","doi-asserted-by":"crossref","first-page":"134","DOI":"10.1038\/ncpendmet0394","article-title":"Drug insight: vitamin D analogs in the treatment of secondary hyperparathyroidism in patients with chronic kidney disease","volume":"3","author":"Brown","year":"2007","journal-title":"Nat. Clin. Pract. Endocrinol. Metab."},{"key":"10.1016\/j.mam.2008.04.001_bib33","doi-asserted-by":"crossref","first-page":"43","DOI":"10.1016\/0026-0495(90)90272-E","article-title":"Long-term treatment with calcitriol in postmenopausal osteoporosis","volume":"39","author":"Caniggia","year":"1990","journal-title":"Metabolism"},{"key":"10.1016\/j.mam.2008.04.001_bib34","doi-asserted-by":"crossref","first-page":"68","DOI":"10.1093\/jn\/128.1.68","article-title":"1,25-Dihydroxycholecalciferol inhibits the progression of arthritis in murine models of human arthritis","volume":"128","author":"Cantorna","year":"1998","journal-title":"J. Nutr."},{"key":"10.1016\/j.mam.2008.04.001_bib35","doi-asserted-by":"crossref","first-page":"7861","DOI":"10.1073\/pnas.93.15.7861","article-title":"1,25-Dihydroxyvitamin D3 reversibly blocks the progression of relapsing encephalomyelitis, a model of multiple sclerosis","volume":"93","author":"Cantorna","year":"1996","journal-title":"Proc. Natl. Acad. Sci. U.S.A."},{"key":"10.1016\/j.mam.2008.04.001_bib36","doi-asserted-by":"crossref","first-page":"2648","DOI":"10.1093\/jn\/130.11.2648","article-title":"1,25-Dihydroxycholecalciferol prevents and ameliorates symptoms of experimental murine inflammatory bowel disease","volume":"130","author":"Cantorna","year":"2000","journal-title":"J. Nutr."},{"key":"10.1016\/j.mam.2008.04.001_bib37","doi-asserted-by":"crossref","first-page":"860","DOI":"10.1359\/jbmr.070305","article-title":"Differential effects of vitamin D analogs on vascular calcification","volume":"22","author":"Cardus","year":"2007","journal-title":"J. Bone. Miner. Res."},{"key":"10.1016\/j.mam.2008.04.001_bib38","doi-asserted-by":"crossref","first-page":"1243","DOI":"10.2174\/156802606777864908","article-title":"Detailed molecular understanding of agonistic and antagonistic vitamin D receptor ligands","volume":"6","author":"Carlberg","year":"2006","journal-title":"Curr. Top. Med. Chem."},{"key":"10.1016\/j.mam.2008.04.001_bib39","doi-asserted-by":"crossref","first-page":"1634","DOI":"10.4049\/jimmunol.179.3.1634","article-title":"Modulatory effects of 1,25-dihydroxyvitamin D3 on human B cell differentiation","volume":"179","author":"Chen","year":"2007","journal-title":"J. Immunol."},{"key":"10.1016\/j.mam.2008.04.001_bib40","doi-asserted-by":"crossref","first-page":"81","DOI":"10.1677\/JME-07-0042","article-title":"Co-chaperone potentiation of vitamin D receptor-mediated transactivation: a role for Bcl2-associated athanogene-1 as an intracellular-binding protein for 1,25-dihydroxyvitamin D3","volume":"39","author":"Chun","year":"2007","journal-title":"J. Mol. Endocrinol."},{"key":"10.1016\/j.mam.2008.04.001_bib41","doi-asserted-by":"crossref","first-page":"8704","DOI":"10.1074\/jbc.M608894200","article-title":"Epigenetic silencing of CYP24 in tumor-derived endothelial cells contributes to selective growth inhibition by calcitriol","volume":"282","author":"Chung","year":"2007","journal-title":"J. Biol. Chem."},{"key":"10.1016\/j.mam.2008.04.001_bib42","doi-asserted-by":"crossref","first-page":"877","DOI":"10.1053\/j.ajkd.2004.01.012","article-title":"Doxercalciferol safely suppresses PTH levels in patients with secondary hyperparathyroidism associated with chronic kidney disease stages 3 and 4","volume":"43","author":"Coburn","year":"2004","journal-title":"Am. J. Kidney Dis."},{"key":"10.1016\/j.mam.2008.04.001_bib43","doi-asserted-by":"crossref","first-page":"1083","DOI":"10.1210\/endo-108-3-1083","article-title":"1,25-dihydroxyvitamin D3 and malignant melanoma: the presence of receptors and inhibition of cell growth in culture","volume":"108","author":"Colston","year":"1981","journal-title":"Endocrinology"},{"key":"10.1016\/j.mam.2008.04.001_bib44","doi-asserted-by":"crossref","first-page":"693","DOI":"10.1016\/0006-2952(92)90405-8","article-title":"Effects of synthetic vitamin D analogues on breast cancer cell proliferation in vivo and in vitro","volume":"44","author":"Colston","year":"1992","journal-title":"Biochem. Pharmacol."},{"key":"10.1016\/j.mam.2008.04.001_bib45","doi-asserted-by":"crossref","first-page":"1017","DOI":"10.1038\/bjc.1997.501","article-title":"Vitamin D receptors and anti-proliferative effects of vitamin D derivatives in human pancreatic carcinoma cells in vivo and in vitro","volume":"76","author":"Colston","year":"1997","journal-title":"Br. J. Cancer"},{"key":"10.1016\/j.mam.2008.04.001_bib46","doi-asserted-by":"crossref","first-page":"2273","DOI":"10.1016\/0006-2952(92)90669-A","article-title":"EB1089: a new vitamin D analogue that inhibits the growth of breast cancer cells in vivo and in vitro","volume":"44","author":"Colston","year":"1992","journal-title":"Biochem. Pharmacol."},{"key":"10.1016\/j.mam.2008.04.001_bib47","doi-asserted-by":"crossref","first-page":"263","DOI":"10.1053\/j.ajkd.2005.10.007","article-title":"Paricalcitol capsule for treatment of secondary hyperparathyroidism in stages 3 and 4 CKD","volume":"47","author":"Coyne","year":"2006","journal-title":"Am. J. Kidney Dis."},{"key":"10.1016\/j.mam.2008.04.001_bib48","doi-asserted-by":"crossref","first-page":"2109","DOI":"10.1046\/j.1523-1755.2001.00042.x","article-title":"p21WAF1 and TGFa mediate the parathyroid growth arrest by vitamin D and high calcium","volume":"60","author":"Cozzolino","year":"2001","journal-title":"Kidney Int."},{"key":"10.1016\/j.mam.2008.04.001_bib49","doi-asserted-by":"crossref","first-page":"591","DOI":"10.1530\/eje.0.1500591","article-title":"Inhibition of prostate cell growth by BXL-628, a calcitriol analogue selected for a phase II clinical trial in patients with benign prostate hyperplasia","volume":"150","author":"Crescioli","year":"2004","journal-title":"Eur. J. Endocrinol."},{"key":"10.1016\/j.mam.2008.04.001_bib50","doi-asserted-by":"crossref","first-page":"684","DOI":"10.1038\/nrc2196","article-title":"Vitamin D signalling pathways in cancer: potential for anticancer therapeutics","volume":"7","author":"Deeb","year":"2007","journal-title":"Nat. Rev. Cancer"},{"key":"10.1016\/j.mam.2008.04.001_bib51","doi-asserted-by":"crossref","first-page":"2786","DOI":"10.1158\/1535-7163.MCT-06-0316","article-title":"Potentiation of radiation sensitivity in breast tumor cells by the vitamin D3 analogue, EB 1089, through promotion of autophagy and interference with proliferative recovery","volume":"5","author":"Demasters","year":"2006","journal-title":"Mol. Cancer Ther."},{"key":"10.1016\/j.mam.2008.04.001_bib52","doi-asserted-by":"crossref","first-page":"987","DOI":"10.1016\/0006-2952(94)90409-X","article-title":"Increased biological activity of 20-epi-1,25-dihydroxyvitamin D3 is due to reduced catabolism and altered protein binding","volume":"47","author":"Dilworth","year":"1994","journal-title":"Biochem. Pharmacol."},{"key":"10.1016\/j.mam.2008.04.001_bib53","doi-asserted-by":"crossref","first-page":"5485","DOI":"10.1210\/en.138.12.5485","article-title":"The vitamin D analog, KH1060, is rapidly degraded both in vivo and in vitro via several pathways: principal metabolites generated retain significant biological activity","volume":"138","author":"Dilworth","year":"1997","journal-title":"Endocrinology"},{"key":"10.1016\/j.mam.2008.04.001_bib54","doi-asserted-by":"crossref","first-page":"451","DOI":"10.1016\/j.jsbmb.2006.11.016","article-title":"In vivo relevance for photoprotection by the vitamin D rapid response pathway","volume":"103","author":"Dixon","year":"2007","journal-title":"J. Steroid Biochem. Mol. Biol."},{"key":"10.1016\/j.mam.2008.04.001_bib55","doi-asserted-by":"crossref","first-page":"1174","DOI":"10.1093\/ndt\/gfh123","article-title":"Paricalcitol-treated patients experience improved hospitalization outcomes compared with calcitriol-treated patients in real-world clinical settings","volume":"19","author":"Dobrez","year":"2004","journal-title":"Nephrol. Dial. Transplant."},{"key":"10.1016\/j.mam.2008.04.001_bib56","doi-asserted-by":"crossref","first-page":"F8","DOI":"10.1152\/ajprenal.00336.2004","article-title":"Vitamin D","volume":"289","author":"Dusso","year":"2005","journal-title":"Am. J. Physiol. Renal Physiol."},{"key":"10.1016\/j.mam.2008.04.001_bib57","doi-asserted-by":"crossref","first-page":"1893","DOI":"10.2174\/092986707781058823","article-title":"Mechanism and potential of the growth-inhibitory actions of vitamin D and analogs","volume":"14","author":"Eelen","year":"2007","journal-title":"Curr. Med. Chem."},{"key":"10.1016\/j.mam.2008.04.001_bib58","doi-asserted-by":"crossref","first-page":"133","DOI":"10.1359\/jbmr.0301204","article-title":"The effects of 1alpha,25-dihydroxyvitamin D3 on the expression of DNA replication genes","volume":"19","author":"Eelen","year":"2004","journal-title":"J. Bone Miner. Res."},{"key":"10.1016\/j.mam.2008.04.001_bib59","first-page":"21","article-title":"Suppression of in vivo growth of human cancer solid tumor xenografts by 1,25-dihydroxyvitamin D3","volume":"47","author":"Eisman","year":"1987","journal-title":"Cancer Res."},{"key":"10.1016\/j.mam.2008.04.001_bib60","doi-asserted-by":"crossref","first-page":"9","DOI":"10.1016\/j.bbrc.2005.06.054","article-title":"Promoter-, cell-, and ligand-specific transactivation responses of the VDRB1 isoform","volume":"334","author":"Esteban","year":"2005","journal-title":"Biochem. Biophys. Res. Commun."},{"key":"10.1016\/j.mam.2008.04.001_bib61","doi-asserted-by":"crossref","first-page":"1943","DOI":"10.1093\/ndt\/15.12.1943","article-title":"Potent suppression of the parathyroid glands by hydroxylated metabolites of dihydrotachysterol(2)","volume":"15","author":"Fan","year":"2000","journal-title":"Neprhol. Dial. Transplant."},{"key":"10.1016\/j.mam.2008.04.001_bib62","first-page":"F705","article-title":"22-Oxacalcitriol: dissection of 1,25(OH)2D3 receptor-mediated and Ca2+ entry-stimulating pathways","volume":"265","author":"Farach-Carson","year":"1993","journal-title":"Am. J. Physiol."},{"key":"10.1016\/j.mam.2008.04.001_bib63","doi-asserted-by":"crossref","first-page":"67","DOI":"10.2174\/1389450033347118","article-title":"Membrane receptors for vitamin D steroid hormones: potential new drug targets","volume":"4","author":"Farach-Carson","year":"2003","journal-title":"Curr. Drug Targets"},{"key":"10.1016\/j.mam.2008.04.001_bib64","doi-asserted-by":"crossref","first-page":"239","DOI":"10.1016\/j.jss.2007.02.038","article-title":"A vitamin D analogue inhibits colonic carcinogenesis in the AOM\/DSS model","volume":"142","author":"Fichera","year":"2007","journal-title":"J. Surg. Res."},{"key":"10.1016\/j.mam.2008.04.001_bib65","doi-asserted-by":"crossref","first-page":"68","DOI":"10.1093\/ndt\/13.suppl_3.68","article-title":"Intermittent oral 1ahydroxyvitamin D2 is effective and safe for the suppression of secondary hyperparathyroidism in haemodialysis patients","volume":"3","author":"Frazao","year":"1998","journal-title":"Nephrol. Dial. Transplant."},{"key":"10.1016\/j.mam.2008.04.001_bib66","doi-asserted-by":"crossref","first-page":"39","DOI":"10.1016\/0026-0495(90)90271-D","article-title":"Studies of osteoporosis in Japan","volume":"39","author":"Fujita","year":"1990","journal-title":"Metabolism"},{"key":"10.1016\/j.mam.2008.04.001_bib67","doi-asserted-by":"crossref","first-page":"8433","DOI":"10.1074\/jbc.272.13.8433","article-title":"Functional characterization and purification of an intracellular vitamin D-binding protein in vitamin D-resistant new world primate cells. Amino acid sequence homology with proteins in the hsp-70 family","volume":"272","author":"Gacad","year":"1997","journal-title":"J. Biol. Chem."},{"key":"10.1016\/j.mam.2008.04.001_bib68","doi-asserted-by":"crossref","first-page":"3325","DOI":"10.1073\/pnas.79.10.3325","article-title":"1,25-Dihydroxyvitamin D3: short- and long-term effects on bone and calcium metabolism in patients with postmenopausal osteoporosis","volume":"79","author":"Gallagher","year":"1982","journal-title":"Proc. National Acad. Sci. U.S.A."},{"key":"10.1016\/j.mam.2008.04.001_bib69","doi-asserted-by":"crossref","first-page":"227","DOI":"10.1093\/ije\/9.3.227","article-title":"Do sunlight and vitamin D reduce the likelihood of colon cancer?","volume":"9","author":"Garland","year":"1980","journal-title":"Int. J. Epidemiol."},{"key":"10.1016\/j.mam.2008.04.001_bib70","doi-asserted-by":"crossref","first-page":"614","DOI":"10.1016\/0091-7435(90)90058-R","article-title":"Geographic variation in breast cancer mortality in the United States: a hypothesis involving exposure to solar radiation","volume":"19","author":"Garland","year":"1990","journal-title":"Prevent. Med."},{"key":"10.1016\/j.mam.2008.04.001_bib71","doi-asserted-by":"crossref","first-page":"2028","DOI":"10.1210\/me.2003-0072","article-title":"Corepressor excess shifts the two-side chain vitamin D analog Gemini from an agonist to an inverse agonist of the vitamin D receptor","volume":"17","author":"Gonzalez","year":"2003","journal-title":"Mol. Endocrinol."},{"key":"10.1016\/j.mam.2008.04.001_bib72","doi-asserted-by":"crossref","first-page":"1367","DOI":"10.2337\/diabetes.51.5.1367","article-title":"A 1alpha,25-dihydroxyvitamin D(3) analog enhances regulatory T-cells and arrests autoimmune diabetes in NOD mice","volume":"51","author":"Gregori","year":"2002","journal-title":"Diabetes"},{"key":"10.1016\/j.mam.2008.04.001_bib73","unstructured":"Gross, C., Peehl, D.M., Feldman, D., 1997. Vitamin D and prostate cancer. In: Feldman, D., Pike, J.W., Glorieux, F.H. (Eds.), Vitamin D. Academic Press, San Diego, pp. 1125\u20131139."},{"key":"10.1016\/j.mam.2008.04.001_bib74","doi-asserted-by":"crossref","first-page":"274","DOI":"10.1016\/j.abb.2006.09.028","article-title":"Methyl substitution of the 25-hydroxy group on 2-methylene-19-nor-1alpha,25-dihydroxyvitamin D3 (2MD) reduces potency but allows bone selectivity","volume":"460","author":"Grzywacz","year":"2007","journal-title":"Arch. Biochem. Biophys."},{"key":"10.1016\/j.mam.2008.04.001_bib75","doi-asserted-by":"crossref","first-page":"1173","DOI":"10.1016\/S0006-2952(97)00181-0","article-title":"EB1089, a novel vitamin D analog with strong anti-proliferative and differentiation-inducing effects on target cells","volume":"54","author":"Hansen","year":"1997","journal-title":"Biochem. Pharmacol."},{"key":"10.1016\/j.mam.2008.04.001_bib76","doi-asserted-by":"crossref","first-page":"2067","DOI":"10.1093\/ndt\/gfh329","article-title":"Comparison of the effects of calcitriol and maxacalcitol on secondary hyperparathyroidism in patients on chronic haemodialysis: a randomized prospective multicentre trial","volume":"19","author":"Hayashi","year":"2004","journal-title":"Nephrol. Dial. Transplant."},{"issue":"suppl 10","key":"10.1016\/j.mam.2008.04.001_bib77","doi-asserted-by":"crossref","first-page":"41","DOI":"10.1093\/ndt\/17.suppl_10.41","article-title":"A comparison between 1,25-dihydroxy-22-oxavitamin D3 and 1,25-dihydroxyvitamin D3 regarding suppression of parathyroid hormone and calcemic action","volume":"17","author":"Hirata","year":"2002","journal-title":"Nephrol. Dial. Transplant."},{"key":"10.1016\/j.mam.2008.04.001_bib78","doi-asserted-by":"crossref","first-page":"2040","DOI":"10.1046\/j.1523-1755.1999.00772.x","article-title":"22-Oxacalcitriol ameliorates high-turnover bone and marked osteitis fibrosa in rats with slowly progressive nephritis","volume":"56","author":"Hirata","year":"1999","journal-title":"Kidney Int."},{"key":"10.1016\/j.mam.2008.04.001_bib79","doi-asserted-by":"crossref","first-page":"201","DOI":"10.1073\/pnas.80.1.201","article-title":"1 alpha,25-Dihydroxyvitamin D3 and 1 alpha-hydroxyvitamin D3 prolong survival time of mice inoculated with myeloid leukemia cells","volume":"80","author":"Honma","year":"1983","journal-title":"Proc. Natl. Acad. Sci. U.S.A."},{"key":"10.1016\/j.mam.2008.04.001_bib80","doi-asserted-by":"crossref","first-page":"1297","DOI":"10.1038\/sj.cdd.4401651","article-title":"Vitamin D analog EB1089 triggers dramatic lysosomal changes and Beclin 1-mediated autophagic cell death","volume":"12","author":"Hoyer-Hansen","year":"2005","journal-title":"Cell Death Differ"},{"key":"10.1016\/j.mam.2008.04.001_bib81","doi-asserted-by":"crossref","first-page":"1781","DOI":"10.1093\/oxfordjournals.ndt.a027668","article-title":"Effects of new vitamin D analogues on parathyroid function in chronically uraemic rats with secondary hyperparathyroidism","volume":"11","author":"Hruby","year":"1996","journal-title":"Nephrol. Dial. Transplant."},{"key":"10.1016\/j.mam.2008.04.001_bib82","doi-asserted-by":"crossref","first-page":"309","DOI":"10.1111\/j.1525-139X.2007.00300.x","article-title":"Renal osteodystrophy, phosphate homeostasis, and vascular calcification","volume":"20","author":"Hruska","year":"2007","journal-title":"Semin. Dial."},{"key":"10.1016\/j.mam.2008.04.001_bib83","doi-asserted-by":"crossref","first-page":"243","DOI":"10.1016\/S0960-0760(99)00112-0","article-title":"Increased biological potency of hexafluorinated analogs of 1,25-dihydroxyvitamin D3 on bovine parathyroid cells","volume":"70","author":"Imanishi","year":"1999","journal-title":"J. Steroid Biochem. Mol. Biol."},{"key":"10.1016\/j.mam.2008.04.001_bib84","doi-asserted-by":"crossref","first-page":"139","DOI":"10.1185\/030079907X253519","article-title":"Molecular basis of the potential of vitamin D to prevent cancer","volume":"24","author":"Ingraham","year":"2008","journal-title":"Curr. Med. Res. Opin."},{"key":"10.1016\/j.mam.2008.04.001_bib85","doi-asserted-by":"crossref","first-page":"730","DOI":"10.1002\/(SICI)1097-0215(19990531)81:5<730::AID-IJC11>3.0.CO;2-Q","article-title":"Inhibition of angiogenesis as a mechanism for inhibition by 1alpha-hydroxyvitamin D3 and 1,25-dihydroxyvitamin D3 of colon carcinogenesis induced by azoxymethane in Wistar rats","volume":"81","author":"Iseki","year":"1999","journal-title":"Int. J. Cancer"},{"key":"10.1016\/j.mam.2008.04.001_bib86","doi-asserted-by":"crossref","first-page":"53213","DOI":"10.1074\/jbc.M410395200","article-title":"Induction of ovarian cancer cell apoptosis by 1,25-dihydroxyvitamin D3 through the down-regulation of telomerase","volume":"279","author":"Jiang","year":"2004","journal-title":"J. Biol. Chem."},{"key":"10.1016\/j.mam.2008.04.001_bib87","doi-asserted-by":"crossref","first-page":"245","DOI":"10.1016\/0966-3274(95)80031-X","article-title":"The effects of combined treatment with the novel vitamin D analogue MC 1288 and cyclosporine A on cardiac allograft survival","volume":"3","author":"Johnsson","year":"1995","journal-title":"Transplant Immunol."},{"key":"10.1016\/j.mam.2008.04.001_bib88","doi-asserted-by":"crossref","first-page":"335","DOI":"10.5414\/CNP65335","article-title":"Differential effects of very high doses of doxercalciferol and paricalcitol on serum phosphorus in hemodialysis patients","volume":"65","author":"Joist","year":"2006","journal-title":"Clin. Nephrol."},{"key":"10.1016\/j.mam.2008.04.001_bib89","doi-asserted-by":"crossref","first-page":"2719","DOI":"10.1210\/en.133.6.2719","article-title":"Differential catabolism of 22-oxacalcitriol and 1,25-dihydroxyvitamin D3 by normal human peripheral monocytes","volume":"133","author":"Kamimura","year":"1993","journal-title":"Endocrinology"},{"key":"10.1016\/j.mam.2008.04.001_bib90","doi-asserted-by":"crossref","first-page":"1605","DOI":"10.1053\/gast.1996.v110.pm8613068","article-title":"Inhibitory effect of 22-oxa-1,25-dihydroxyvitamin D3 on the proliferation of pancreatic cancer cell lines","volume":"110","author":"Kawa","year":"1996","journal-title":"Gastroenterology"},{"key":"10.1016\/j.mam.2008.04.001_bib91","doi-asserted-by":"crossref","first-page":"1742","DOI":"10.1359\/JBMR.050605","article-title":"A new vitamin D analog, 2MD, restores trabecular and cortical bone mass and strength in ovariectomized rats with established osteopenia","volume":"20","author":"Ke","year":"2005","journal-title":"J. Bone Miner. Res."},{"key":"10.1016\/j.mam.2008.04.001_bib92","doi-asserted-by":"crossref","first-page":"1087","DOI":"10.2174\/092986707780362871","article-title":"The ERp57\/GRp58\/1,25D3-MARRS receptor: multiple functional roles in diverse cell systems","volume":"14","author":"Khanal","year":"2007","journal-title":"Curr. Med. Chem."},{"key":"10.1016\/j.mam.2008.04.001_bib93","doi-asserted-by":"crossref","first-page":"129","DOI":"10.1159\/000420168","article-title":"Metabolism and transporting system of 22-oxacalcitriol","volume":"91","author":"Kobayashi","year":"1991","journal-title":"Contribut. Nephrol."},{"key":"10.1016\/j.mam.2008.04.001_bib94","doi-asserted-by":"crossref","first-page":"1259","DOI":"10.1016\/j.leukres.2005.04.003","article-title":"Vitamin D(2) analog (paricalcitol; Zemplar) for treatment of myelodysplastic syndrome","volume":"29","author":"Koeffler","year":"2005","journal-title":"Leuk. Res."},{"key":"10.1016\/j.mam.2008.04.001_bib95","first-page":"1399","article-title":"1,25-Dihydroxyvitamin D3: in vivo and in vitro effects on human preleukemic and leukemic cells","volume":"69","author":"Koeffler","year":"1985","journal-title":"Cancer Treat. Rep."},{"key":"10.1016\/j.mam.2008.04.001_bib96","doi-asserted-by":"crossref","first-page":"396","DOI":"10.1159\/000233815","article-title":"Effects of corticosteroid and 1,24R-dihydroxy-vitamin D3 administration on lymphoproliferation and autoimmune disease in MRL\/MP-lpr\/lpr mice","volume":"77","author":"Koizumi","year":"1985","journal-title":"Int. Arch. Allergy Appl. Immunol."},{"key":"10.1016\/j.mam.2008.04.001_bib97","doi-asserted-by":"crossref","first-page":"973","DOI":"10.1124\/dmd.31.8.973","article-title":"Disposition and metabolism of F6-1alpha,25(OH)2 vitamin D3 and 1alpha,25(OH)2 vitamin D3 in the parathyroid glands of rats dosed with tritium-labeled compounds","volume":"31","author":"Komuro","year":"2003","journal-title":"Drug Metab. Dispos."},{"key":"10.1016\/j.mam.2008.04.001_bib98","doi-asserted-by":"crossref","unstructured":"Koshizuka, K., Koike, M., Asou, H., Cho, Sk., Stephen, T., Rude, Rk., Binderup, L. Uskokovic MKoeffler Hp., 1999. Combined effect of vitamin D3 analogs and paclitaxel on the growth of MCF-7 breast cancer cells in vivo. Breast Cancer Res. Treat. 53, 113\u2013120.","DOI":"10.1023\/A:1006123819675"},{"key":"10.1016\/j.mam.2008.04.001_bib99","doi-asserted-by":"crossref","first-page":"164","DOI":"10.1007\/BF00372616","article-title":"Calcipotriol (MC 903), a novel vitamin D3 analogue stimulates terminal differentiation and inhibits proliferation of cultured human keratinocytes","volume":"282","author":"Kragballe","year":"1990","journal-title":"Arch. Dermatol. Res."},{"key":"10.1016\/j.mam.2008.04.001_bib100","doi-asserted-by":"crossref","first-page":"694","DOI":"10.1016\/j.jsbmb.2006.12.051","article-title":"Novel pathways that contribute to the anti-proliferative and chemopreventive activities of calcitriol in prostate cancer","volume":"103","author":"Krishnan","year":"2007","journal-title":"J. Steroid Biochem. Mol. Biol."},{"key":"10.1016\/j.mam.2008.04.001_bib101","doi-asserted-by":"crossref","first-page":"1910","DOI":"10.1016\/S0021-9258(18)52379-6","article-title":"Induction of calbindin-D 9k mRNA but not calcium transport in rat intestine by 1,25-dihydroxyvitamin D3 24-homologs","volume":"266","author":"Krisinger","year":"1991","journal-title":"J. Biol. Chem."},{"key":"10.1016\/j.mam.2008.04.001_bib102","doi-asserted-by":"crossref","first-page":"896","DOI":"10.1093\/jnci\/95.12.896","article-title":"Vitamin D2 analog 19-nor-1,25-dihydroxyvitamin D2: antitumor activity against leukemia, myeloma, and colon cancer cells","volume":"95","author":"Kumagai","year":"2003","journal-title":"J. Natl. Cancer Inst."},{"key":"10.1016\/j.mam.2008.04.001_bib103","doi-asserted-by":"crossref","first-page":"277","DOI":"10.1046\/j.1365-2249.1998.00706.x","article-title":"A vitamin D analogue (MC 1288) has immunomodulatory properties and suppresses collagen-induced arthritis (CIA) without causing hypercalcaemia","volume":"114","author":"Larsson","year":"1998","journal-title":"Clin. Exp. Immunol."},{"key":"10.1016\/j.mam.2008.04.001_bib104","doi-asserted-by":"crossref","first-page":"1103","DOI":"10.1172\/JCI115072","article-title":"1,25-dihydroxyvitamin D3 prevents the in vivo induction of murine experimental autoimmune encephalomyelitis","volume":"87","author":"Lemire","year":"1991","journal-title":"J. Clin. Invest."},{"key":"10.1016\/j.mam.2008.04.001_bib105","doi-asserted-by":"crossref","first-page":"2818","DOI":"10.1210\/en.135.6.2818","article-title":"1,25-Dihydroxy-24-oxo-16-ene-vitamin D3, a renal metabolite of the vitamin D analog 1,25-dihydroxy-16-ene-vitamin D3, exerts immunosuppressive activity equal to its parent without causing hypercalcemia in vivo","volume":"135","author":"Lemire","year":"1994","journal-title":"Endocrinology"},{"key":"10.1016\/j.mam.2008.04.001_bib106","doi-asserted-by":"crossref","first-page":"143","DOI":"10.3109\/08916939209150321","article-title":"1,25-Dihydroxyvitamin D3 attenuates the expression of experimental murine lupus of MRL\/l mice","volume":"12","author":"Lemire","year":"1992","journal-title":"Autoimmunity"},{"key":"10.1016\/j.mam.2008.04.001_bib107","doi-asserted-by":"crossref","first-page":"7","DOI":"10.1159\/000075191","article-title":"1,25-(OH)2-16-ene-23yne-D3 reduces secondary hyperparathyroidism in uremic rats with little calcemic effect","volume":"61","author":"Lippuner","year":"2004","journal-title":"Horm. Res."},{"key":"10.1016\/j.mam.2008.04.001_bib108","doi-asserted-by":"crossref","first-page":"1770","DOI":"10.1126\/science.1123933","article-title":"Toll-like receptor triggering of a vitamin D-mediated human antimicrobial response","volume":"311","author":"Liu","year":"2006","journal-title":"Science"},{"key":"10.1016\/j.mam.2008.04.001_bib11a","first-page":"5621","article-title":"Chemopreventive activity of tamoxifen, N-(4-hydroxyphenyl)retinamide, and the vitamin D analogue RO24-5531 for adrogen-promoted carcinomas of the rat seminal vesicle and prostate","volume":"55","author":"Lucia","year":"1995","journal-title":"Cancer Res."},{"key":"10.1016\/j.mam.2008.04.001_bib109","doi-asserted-by":"crossref","first-page":"214","DOI":"10.1161\/01.RES.87.3.214","article-title":"1 alpha,25-dihydroxyvitamin D(3) inhibits angiogenesis in vitro and in vivo","volume":"87","author":"Mantell","year":"2000","journal-title":"Circ. Res."},{"key":"10.1016\/j.mam.2008.04.001_bib110","doi-asserted-by":"crossref","first-page":"1427","DOI":"10.1681\/ASN.V981427","article-title":"19-Nor-1a,25-dihydroxyvitamin D2 (Paricalcitol) safely and effectively reduces the levels of intact parathyroid hormone in patients on hemodialysis","volume":"9","author":"Martin","year":"1998","journal-title":"J. Am. Soc. Nephrol."},{"key":"10.1016\/j.mam.2008.04.001_bib111","doi-asserted-by":"crossref","first-page":"S 61","DOI":"10.1053\/ajkd.1998.v32.pm9808145","article-title":"Therapy of secondary hyperparathyroidism with 19-nor-1a,25-dihydroxyvitamin D2","volume":"32","author":"Martin","year":"1998","journal-title":"Am. J. Kidney Diseases"},{"key":"10.1016\/j.mam.2008.04.001_bib112","doi-asserted-by":"crossref","first-page":"41","DOI":"10.1159\/000211329","article-title":"Regulatory effects of antipsoriatic agents on interleukin-1 alpha production by human keratinocytes stimulated with gamma interferon in vitro","volume":"8","author":"Maruyama","year":"1995","journal-title":"Skin Pharmacol."},{"key":"10.1016\/j.mam.2008.04.001_bib113","doi-asserted-by":"crossref","first-page":"866","DOI":"10.1210\/en.136.3.866","article-title":"Prevention of type I diabetes in NOD mice by nonhypercalcemic doses of a new structural analog of 1,25-dihydroxyvitamin D3, KH1060","volume":"136","author":"Mathieu","year":"1995","journal-title":"Endocrinology"},{"key":"10.1016\/j.mam.2008.04.001_bib114","doi-asserted-by":"crossref","first-page":"552","DOI":"10.1007\/BF00403372","article-title":"Prevention of autoimmune diabetes in NOD mice by 1,25 dihydroxyvitamin D3","volume":"37","author":"Mathieu","year":"1994","journal-title":"Diabetologia"},{"key":"10.1016\/j.mam.2008.04.001_bib115","doi-asserted-by":"crossref","first-page":"584","DOI":"10.1016\/j.jsbmb.2006.12.088","article-title":"ED-71, a new active vitamin D3, increases bone mineral density regardless of serum 25(OH)D levels in osteoporotic subjects","volume":"103","author":"Matsumoto","year":"2007","journal-title":"J. Steroid Biochem. Mol. Biol."},{"key":"10.1016\/j.mam.2008.04.001_bib116","doi-asserted-by":"crossref","first-page":"135","DOI":"10.1111\/j.1346-8138.1990.tb01614.x","article-title":"1,24(R)-dihydroxyvitamin D3, a novel active form of vitamin D3 with high activity for inducing epidermal differentiation but decreased hypercalcemic activity","volume":"17","author":"Matsunaga","year":"1990","journal-title":"J. Dermatol."},{"key":"10.1016\/j.mam.2008.04.001_bib117","doi-asserted-by":"crossref","first-page":"498","DOI":"10.1002\/1521-4141(200002)30:2<498::AID-IMMU498>3.0.CO;2-Q","article-title":"Inhibition of Th1 development and treatment of chronic-relapsing experimental allergic encephalomyelitis by a non-hypercalcemic analogue of 1,25-dihydroxyvitamin D(3)","volume":"30","author":"Mattner","year":"2000","journal-title":"Eur. J. Immunol."},{"key":"10.1016\/j.mam.2008.04.001_bib118","first-page":"761","article-title":"Treatment of myelodysplastic syndrome with alfacalcidol","volume":"2","author":"Metha","year":"1984","journal-title":"Lancet"},{"key":"10.1016\/j.mam.2008.04.001_bib119","doi-asserted-by":"crossref","first-page":"709","DOI":"10.1038\/sj.ki.5002406","article-title":"Differential effects of vitamin D receptor activators on vascular calcification in uremic rats","volume":"72","author":"Mizobuchi","year":"2007","journal-title":"Kidney Int."},{"key":"10.1016\/j.mam.2008.04.001_bib120","doi-asserted-by":"crossref","first-page":"69","DOI":"10.1016\/j.jsbmb.2005.06.025","article-title":"A perspective on how the vitamin D sterol\/vitamin D receptor (VDR) conformational ensemble model can potentially be used to understand the structure-function results of A-ring modified vitamin D sterols","volume":"97","author":"Mizwicki","year":"2005","journal-title":"J. Steroid Biochem. Mol. Biol."},{"key":"10.1016\/j.mam.2008.04.001_bib121","doi-asserted-by":"crossref","first-page":"821","DOI":"10.1046\/j.1523-1755.1999.055003821.x","article-title":"22-oxacalcitriol suppresses secondary hyperparathyroidism without inducing low bone turnover in dogs with renal failure","volume":"55","author":"Monier-Faugere","year":"1999","journal-title":"Kidney Int."},{"key":"10.1016\/j.mam.2008.04.001_bib122","first-page":"1143","article-title":"Comparison of the inhibitions of proliferation of normal and psoriatic fibroblasts by 1 alpha,25-dihydroxyvitamin D3 and synthetic analogues of vitamin D3 with an oxygen atom in their side chain","volume":"19","author":"Morimoto","year":"1989","journal-title":"Biochem. Int."},{"key":"10.1016\/j.mam.2008.04.001_bib123","doi-asserted-by":"crossref","first-page":"67","DOI":"10.1002\/ajh.2830380112","article-title":"The effect of 1-hydroxyvitamin D3 for prolongation of leukemic transformation-free survival in myelodysplastic syndromes","volume":"38","author":"Motomura","year":"1991","journal-title":"Am. J. Hematol."},{"key":"10.1016\/j.mam.2008.04.001_bib124","doi-asserted-by":"crossref","first-page":"4410","DOI":"10.1248\/cpb.34.4410","article-title":"Synthetic studies of vitamin D3 analogues. VIII. Synthesis of 22-oxavitamin D3 analogues","volume":"34","author":"Murayama","year":"1986","journal-title":"Chem. Pharm. Bull."},{"key":"10.1016\/j.mam.2008.04.001_bib125","doi-asserted-by":"crossref","first-page":"129","DOI":"10.1016\/j.jsbmb.2005.06.008","article-title":"Chemoprevention of chemically-induced mammary and colon carcinogenesis by 1alpha-hydroxyvitamin D5","volume":"97","author":"Murillo","year":"2005","journal-title":"J. Steroid Biochem. Mol. Biol."},{"key":"10.1016\/j.mam.2008.04.001_bib126","doi-asserted-by":"crossref","first-page":"1044","DOI":"10.1093\/carcin\/bgi049","article-title":"22-Oxa-1alpha,25-dihydroxyvitamin D3 inhibits metastasis and angiogenesis in lung cancer","volume":"26","author":"Nakagawa","year":"2005","journal-title":"Carcinogenesis"},{"key":"10.1016\/j.mam.2008.04.001_bib127","doi-asserted-by":"crossref","first-page":"2724","DOI":"10.1210\/en.133.6.2724","article-title":"Effects of calcitriol, 22-oxacalcitriol, and calcipotriol on serum calcium and parathyroid hormone gene expression","volume":"133","author":"Naveh-Many","year":"1993","journal-title":"Endocrinology"},{"key":"10.1016\/j.mam.2008.04.001_bib128","doi-asserted-by":"crossref","unstructured":"Nijenhuis, T., van der Eerden, B.C., Zugel, U., Steinmeyer, A., Weinans, H., Hoenderop, J.G., van Leeuwen, J.P., Bindels, R.J., 2006. The novel vitamin D analog ZK191784 as an intestine-specific vitamin D antagonist. FASEB J.","DOI":"10.1096\/fj.05-5155fje"},{"key":"10.1016\/j.mam.2008.04.001_bib129","first-page":"166","article-title":"Tacalcitol ointment for psoriasis","volume":"186","author":"Nishimura","year":"1994","journal-title":"Acta Dermato \u2013 Venereol. Suppl."},{"key":"10.1016\/j.mam.2008.04.001_bib130","doi-asserted-by":"crossref","first-page":"196","DOI":"10.1159\/000420143","article-title":"Clinical trial of 26,26,26,27,27,27-hexafluoro-1,25-dihydroxyvitamin D3 in uremic patients on hemodialysis: preliminary report","volume":"90","author":"Nishizawa","year":"1991","journal-title":"Contribut. Nephrol."},{"key":"10.1016\/j.mam.2008.04.001_bib131","doi-asserted-by":"crossref","first-page":"107","DOI":"10.1016\/j.jsbmb.2006.04.003","article-title":"Novel Gemini-vitamin D3 analog inhibits tumor cell growth and modulates the Akt\/mTOR signaling pathway","volume":"100","author":"O\u2019Kelly","year":"2006","journal-title":"J. Steroid Biochem. Mol. Biol."},{"key":"10.1016\/j.mam.2008.04.001_bib132","doi-asserted-by":"crossref","first-page":"202","DOI":"10.1111\/j.1744-9987.2007.00422.x","article-title":"Effects of 22-oxacalcitriol and calcitriol on PTH secretion and bone mineral metabolism in a crossover trial in hemodialysis patients with secondary hyperparathyroidism","volume":"11","author":"Ogata","year":"2007","journal-title":"Ther. Apher. Dial."},{"key":"10.1016\/j.mam.2008.04.001_bib133","doi-asserted-by":"crossref","first-page":"475","DOI":"10.1097\/00001813-199110000-00007","article-title":"Antitumor effect of 22-oxa-1 alpha,25-dihydroxyvitamin D3, a potent angiogenesis inhibitor, on rat mammary tumors induced by 7,12-dimethylbenz[a]anthracene","volume":"2","author":"Oikawa","year":"1991","journal-title":"Anti-Cancer Drugs"},{"key":"10.1016\/j.mam.2008.04.001_bib134","doi-asserted-by":"crossref","first-page":"529","DOI":"10.3177\/jnsv.35.529","article-title":"Protein-binding properties of 22-oxa-1a,25-dihydroxyvitamin D3, a synthetic analogue of 1a,25-dihydroxyvitamin D3","volume":"35","author":"Okano","year":"1989","journal-title":"J. Nutr. Sci. Vitaminol."},{"key":"10.1016\/j.mam.2008.04.001_bib135","first-page":"47","article-title":"Reduced occurrence of vertebral crush fractures in senile osteoporosis treated with 1 alpha (OH)-vitamin D3","volume":"3","author":"Orimo","year":"1987","journal-title":"Bone Miner."},{"key":"10.1016\/j.mam.2008.04.001_bib136","doi-asserted-by":"crossref","first-page":"195","DOI":"10.1016\/1078-1439(95)00061-5","article-title":"Phase II trial of oral 1,25-dihydroxyvitamin D (calcitriol) in hormone refractory prostate cancer","volume":"1","author":"Osborn","year":"1995","journal-title":"Urol. Oncol."},{"key":"10.1016\/j.mam.2008.04.001_bib137","doi-asserted-by":"crossref","first-page":"2091","DOI":"10.1093\/carcin\/16.9.2091","article-title":"Inhibition of intestinal tumor development in rat multi-organ carcinogenesis and aberrant crypt foci in rat colon carcinogenesis by 22-oxa-calcitriol, a synthetic analogue of 1 alpha, 25-dihydroxyvitamin D3","volume":"16","author":"Otoshi","year":"1995","journal-title":"Carcinogenesis"},{"key":"10.1016\/j.mam.2008.04.001_bib138","doi-asserted-by":"crossref","first-page":"267","DOI":"10.7326\/0003-4819-110-4-267","article-title":"Calcitriol treatment is not effective in postmenopausal osteoporosis","volume":"110","author":"Ott","year":"1989","journal-title":"Annals of Internal Medicine"},{"key":"10.1016\/j.mam.2008.04.001_bib139","first-page":"805","article-title":"Antiproliferative effects of 1,25-dihydroxyvitamin D3 on primary cultures of human prostatic cells","volume":"54","author":"Peehl","year":"1994","journal-title":"Cancer Res."},{"key":"10.1016\/j.mam.2008.04.001_bib140","doi-asserted-by":"crossref","first-page":"10551","DOI":"10.1074\/jbc.270.18.10551","article-title":"Distinct conformational changes induced by 20-epi analogues of 1 alpha,25-dihydroxyvitamin D3 are associated with enhanced activation of the vitamin D receptor","volume":"270","author":"Peleg","year":"1995","journal-title":"J. Biol. Chem."},{"key":"10.1016\/j.mam.2008.04.001_bib141","doi-asserted-by":"crossref","first-page":"1147","DOI":"10.1016\/j.chembiol.2004.05.023","article-title":"A structural basis for the species-specific antagonism of 26,23-lactones on vitamin D signaling","volume":"11","author":"Perakyla","year":"2004","journal-title":"Chem. Biol."},{"key":"10.1016\/j.mam.2008.04.001_bib142","doi-asserted-by":"crossref","first-page":"704","DOI":"10.1007\/s00198-005-0036-3","article-title":"2MD, a new anabolic agent for osteoporosis treatment","volume":"17","author":"Plum","year":"2006","journal-title":"Osteoporos Int."},{"key":"10.1016\/j.mam.2008.04.001_bib143","doi-asserted-by":"crossref","first-page":"6900","DOI":"10.1073\/pnas.0401656101","article-title":"Biologically active noncalcemic analogs of 1alpha,25-dihydroxyvitamin D with an abbreviated side chain containing no hydroxyl","volume":"101","author":"Plum","year":"2004","journal-title":"Proc. Natl. Acad. Sci. U.S.A."},{"key":"10.1016\/j.mam.2008.04.001_bib144","doi-asserted-by":"crossref","first-page":"198","DOI":"10.1002\/jcb.20629","article-title":"Anticancer effects of the novel 1alpha, 25-dihydroxyvitamin D3 hybrid analog QW1624F2-2 in human neuroblastoma","volume":"97","author":"Reddy","year":"2006","journal-title":"J. Cell Biochem."},{"key":"10.1016\/j.mam.2008.04.001_bib145","unstructured":"Reddy, G.S., 1997. Target tissue specific metabolism of 1alpha, 25(OH)2 D3 through A-ring modification. In: Norman, A.W., (Ed.), Tenth Workshop on Vitamin D, Strasbourg, France, p. 65."},{"key":"10.1016\/j.mam.2008.04.001_bib146","doi-asserted-by":"crossref","first-page":"1879","DOI":"10.1016\/S0960-894X(00)80124-9","article-title":"Metabolism of 1,25(OH)2-16-ene-D3 in kidney: influence of structural modification of D-ring on side chain metabolism","volume":"3","author":"Reddy","year":"1993","journal-title":"Bioorg. Med. Chem. Lett."},{"key":"10.1016\/j.mam.2008.04.001_bib147","doi-asserted-by":"crossref","first-page":"459","DOI":"10.1016\/0003-9861(89)90240-3","article-title":"Ketoconazole inhibits self-induced metabolism of 1,25-dihydroxyvitamin D3 and amplifies 1,25-dihydroxyvitamin D3 receptor up-regulation in rat osteosarcoma cells","volume":"272","author":"Reinhardt","year":"1989","journal-title":"Arch. Biochem. Biophys."},{"key":"10.1016\/j.mam.2008.04.001_bib148","doi-asserted-by":"crossref","first-page":"175","DOI":"10.1002\/ajh.2830230212","article-title":"Treatment of myelodysplastic syndrome with 1.25-dihydroxy-vitamin D3","volume":"23","author":"Richard","year":"1986","journal-title":"Am. J. Hematol."},{"key":"10.1016\/j.mam.2008.04.001_bib149","doi-asserted-by":"crossref","first-page":"425","DOI":"10.1007\/s00296-006-0288-z","article-title":"Superiority of a combined treatment of Alendronate and Alfacalcidol compared to the combination of Alendronate and plain vitamin D or Alfacalcidol alone in established postmenopausal or male osteoporosis (AAC-Trial)","volume":"27","author":"Ringe","year":"2007","journal-title":"Rheumatol. Int."},{"key":"10.1016\/j.mam.2008.04.001_bib150","doi-asserted-by":"crossref","first-page":"1229","DOI":"10.2174\/156802606777864926","article-title":"Ligand binding domain of vitamin D receptors","volume":"6","author":"Rochel","year":"2006","journal-title":"Curr. Top. Med. Chem."},{"key":"10.1016\/j.mam.2008.04.001_bib151","doi-asserted-by":"crossref","first-page":"425","DOI":"10.1038\/sj.ki.5000168","article-title":"Fibroblast growth factor 23: the making of a hormone","volume":"69","author":"Schiavi","year":"2006","journal-title":"Kidney Int."},{"key":"10.1016\/j.mam.2008.04.001_bib152","doi-asserted-by":"crossref","unstructured":"Schwartz, G.G., Eads, D., Naczki, C., Northrup, S., Chen, T., Koumenis, C., 2007. 19-nor-1alpha,25-Dihydroxyvitamin D2 (Paricalcitol) inhibits the proliferation of human pancreatic cancer cells in vitro and in vivo. Cancer Biol. Ther. 7.","DOI":"10.4161\/cbt.7.3.5418"},{"key":"10.1016\/j.mam.2008.04.001_bib153","doi-asserted-by":"crossref","first-page":"1015","DOI":"10.1093\/carcin\/bgh086","article-title":"Pancreatic cancer cells express 25-hydroxyvitamin D-1 alpha-hydroxylase and their proliferation is inhibited by the prohormone 25-hydroxyvitamin D3","volume":"25","author":"Schwartz","year":"2004","journal-title":"Carcinogenesis"},{"key":"10.1016\/j.mam.2008.04.001_bib154","doi-asserted-by":"crossref","first-page":"365","DOI":"10.1016\/S0090-4295(99)80221-0","article-title":"1,25-Dihydroxy-16-ene-23-yne-vitamin D3 and prostate cancer cell proliferation in vivo","volume":"46","author":"Schwartz","year":"1995","journal-title":"Urology"},{"key":"10.1016\/j.mam.2008.04.001_bib155","doi-asserted-by":"crossref","first-page":"443","DOI":"10.1016\/j.abb.2007.06.015","article-title":"Differential recruitment of coactivators to the vitamin D receptor transcriptional complex by 1alpha,25-dihydroxyvitamin D3 analogs","volume":"465","author":"Schwinn","year":"2007","journal-title":"Arch. Biochem. Biophys."},{"key":"10.1016\/j.mam.2008.04.001_bib156","doi-asserted-by":"crossref","first-page":"783","DOI":"10.1016\/S0006-2952(96)00815-5","article-title":"Metabolism of the vitamin D analog EB1089 by cultured human cells: redirection of hydroxylation site to distal carbons of the side-chain","volume":"53","author":"Shankar","year":"1997","journal-title":"Biochem. Pharmacol."},{"key":"10.1016\/j.mam.2008.04.001_bib157","doi-asserted-by":"crossref","first-page":"3012","DOI":"10.1002\/ijc.21736","article-title":"Cooperative antitumor effects of vitamin D3 derivatives and rosemary preparations in a mouse model of myeloid leukemia","volume":"118","author":"Sharabani","year":"2006","journal-title":"Int. J. Cancer"},{"key":"10.1016\/j.mam.2008.04.001_bib158","doi-asserted-by":"crossref","first-page":"13487","DOI":"10.1073\/pnas.202471299","article-title":"A potent analog of 1a,25-dihydroxyvitamin D3 selectively induces bone formation","volume":"99","author":"Shevde","year":"2002","journal-title":"Proc. Natl. Acad. Sci. U.S.A."},{"key":"10.1016\/j.mam.2008.04.001_bib159","doi-asserted-by":"crossref","first-page":"405","DOI":"10.1016\/S0960-0760(96)00134-3","article-title":"1alpha,25-dihydroxy-24-oxo-16-ene vitamin D3, a metabolite of a synthetic vitamin D3 analog, 1alpha,25-dihydroxy-16-ene vitamin D3, is equipotent to its parent in modulating growth and differentiation of human leukemic cells","volume":"59","author":"Siu-Caldera","year":"1996","journal-title":"J. Steroid Biochem. Mol. Biol."},{"key":"10.1016\/j.mam.2008.04.001_bib160","doi-asserted-by":"crossref","first-page":"432","DOI":"10.3181\/00379727-178-42028","article-title":"1a-Hydroxyvitamin D2 is less toxic than 1a-hydroxyvitamin D3 in the rat","volume":"178","author":"Sjoden","year":"1985","journal-title":"Proc. Soc. Exp. Biol. Med."},{"key":"10.1016\/j.mam.2008.04.001_bib161","doi-asserted-by":"crossref","first-page":"S14","DOI":"10.1046\/j.1523-1755.1999.07304.x","article-title":"Pathogenesis of secondary hyperparathyroidism","volume":"73","author":"Slatopolsky","year":"1999","journal-title":"Kidney Int."},{"key":"10.1016\/j.mam.2008.04.001_bib162","doi-asserted-by":"crossref","first-page":"1277","DOI":"10.1111\/j.1523-1755.2002.kid573.x","article-title":"Differential effects of 19-nor-1,25-(OH)(2)D(2) and 1alpha-hydroxyvitamin D(2) on calcium and phosphorus in normal and uremic rats","volume":"62","author":"Slatopolsky","year":"2002","journal-title":"Kidney Int."},{"key":"10.1016\/j.mam.2008.04.001_bib163","doi-asserted-by":"crossref","first-page":"2020","DOI":"10.1046\/j.1523-1755.2003.00029.x","article-title":"Efficacy of 19-Nor-1,25-(OH)2D2 in the prevention and treatment of hyperparathyroid bone disease in experimental uremia","volume":"63","author":"Slatopolsky","year":"2003","journal-title":"Kidney Int."},{"key":"10.1016\/j.mam.2008.04.001_bib164","doi-asserted-by":"crossref","first-page":"852","DOI":"10.1016\/0272-6386(95)90455-7","article-title":"A new analog of calcitriol, 19-nor-1,25-(OH)2 D2, suppresses parathyroid hormone secretion in uremic rats in the absence of hypercalcemia","volume":"26","author":"Slatopolsky","year":"1995","journal-title":"Am. J. Kidney Diseases"},{"key":"10.1016\/j.mam.2008.04.001_bib165","doi-asserted-by":"crossref","unstructured":"Slatopolsky, E., Finch, J.L., Brown, A.J., Ritter, C.S., Misobuchi, M., Plum, L.A., Clagett-Dame, M., Sicinski, R.R.Deluca, H.F., 2007a. The effect of 2-methylene-19-nor-(20S)-1a-hydroxy-bishomopregnacalciferol (2MbisP), an analog of Vitamin D, on Secondary Hyperparathyroidism. J. Bone Miner. Res.","DOI":"10.1359\/jbmr.070202"},{"key":"10.1016\/j.mam.2008.04.001_bib166","doi-asserted-by":"crossref","first-page":"686","DOI":"10.1359\/jbmr.070202","article-title":"Effect of 2-methylene-19-nor-(20S)-1 alpha-hydroxy-bishomopregnacalciferol (2MbisP), an analog of vitamin D, on secondary hyperparathyroidism","volume":"22","author":"Slatopolsky","year":"2007","journal-title":"J. Bone Miner. Res."},{"key":"10.1016\/j.mam.2008.04.001_bib167","doi-asserted-by":"crossref","first-page":"757","DOI":"10.1016\/j.jsbmb.2006.12.040","article-title":"Selective vitamin D receptor modulators and their effects on colorectal tumor growth","volume":"103","author":"Spina","year":"2007","journal-title":"J. Steroid Biochem. Mol. Biol."},{"key":"10.1016\/j.mam.2008.04.001_bib168","doi-asserted-by":"crossref","first-page":"1483","DOI":"10.1046\/j.1523-1755.2003.00878.x","article-title":"Paricalcitol versus calcitriol in the treatment of secondary hyperparathyroidism","volume":"63","author":"Sprague","year":"2003","journal-title":"Kidney Int."},{"key":"10.1016\/j.mam.2008.04.001_bib169","doi-asserted-by":"crossref","first-page":"C13","DOI":"10.1016\/0303-7207(92)90149-Z","article-title":"Novel aspects of hormone action: intracellular ligand supply and its control by a series of tissue-specific enzymes","volume":"83","author":"Stewart","year":"1992","journal-title":"Mol. Cell. Endocrinol."},{"key":"10.1016\/j.mam.2008.04.001_bib170","doi-asserted-by":"crossref","first-page":"105","DOI":"10.1016\/S0272-6386(97)90571-0","article-title":"A new analog of 1,25-(OH)2 D3, 19-nor-1,25-(OH)2 D2, suppresses serum PTH and parathyroid gland growth in uremic rats without elevation of intestinal vitamin D receptor content","volume":"30","author":"Takahashi","year":"1997","journal-title":"Am. J. Kidney Diseases"},{"key":"10.1016\/j.mam.2008.04.001_bib171","doi-asserted-by":"crossref","first-page":"1049","DOI":"10.1128\/MCB.19.2.1049","article-title":"Selective interaction of vitamin D receptor with transcriptional coactivators by a vitamin D analog","volume":"19","author":"Takeyama","year":"1999","journal-title":"Mol. Cell. Biol."},{"key":"10.1016\/j.mam.2008.04.001_bib172","doi-asserted-by":"crossref","first-page":"238","DOI":"10.1007\/s10157-005-0363-x","article-title":"Comparison of the efficacy of an oral calcitriol pulse or intravenous 22-oxacalcitriol therapies in chronic hemodialysis patients","volume":"9","author":"Tamura","year":"2005","journal-title":"Clin. Exp. Nephrol."},{"key":"10.1016\/j.mam.2008.04.001_bib173","doi-asserted-by":"crossref","first-page":"317","DOI":"10.1038\/ki.1997.39","article-title":"Effective suppression of parathyroid hormone by 1a-hydroxy-vitamin D2 in hemodialysis patients with moderate to severe secondary hyperparathyroidism","volume":"51","author":"Tan","year":"1997","journal-title":"Kidney Int."},{"key":"10.1016\/j.mam.2008.04.001_bib174","doi-asserted-by":"crossref","first-page":"325","DOI":"10.1002\/jbmr.5650110306","article-title":"Effects of a synthetic vitamin D analog, ED-71, on bone dynamics and strength in cancellous and cortical bone in prednisolone-treated rats","volume":"11","author":"Tanaka","year":"1996","journal-title":"J. Bone Miner. Res."},{"key":"10.1016\/j.mam.2008.04.001_bib175","first-page":"5148","article-title":"Inhibition of HT-29 human colon cancer growth under the renal capsule of severe combined immunodeficient mice by an analogue of 1,25-dihydroxyvitamin D3, DD-003","volume":"54","author":"Tanaka","year":"1994","journal-title":"Cancer Res."},{"key":"10.1016\/j.mam.2008.04.001_bib176","doi-asserted-by":"crossref","first-page":"446","DOI":"10.1056\/NEJMoa022536","article-title":"Survival of patients undergoing hemodialysis with paricalcitol or calcitriol therapy","volume":"349","author":"Teng","year":"2003","journal-title":"New Engl. J. Med."},{"key":"10.1016\/j.mam.2008.04.001_bib177","doi-asserted-by":"crossref","first-page":"1115","DOI":"10.1681\/ASN.2004070573","article-title":"Activated injectable vitamin D and hemodialysis survival: a historical cohort study","volume":"16","author":"Teng","year":"2005","journal-title":"J. Am. Soc. Nephrol."},{"key":"10.1016\/j.mam.2008.04.001_bib178","first-page":"279A","article-title":"Decreased odds of hospitalization among hemodialysis patients receiving doxercalciferol and paricalcitol versus calcitriol","volume":"16","author":"Tentori","year":"2005","journal-title":"J. Am. Soc. Nephrol."},{"key":"10.1016\/j.mam.2008.04.001_bib179","doi-asserted-by":"crossref","first-page":"1858","DOI":"10.1038\/sj.ki.5001868","article-title":"Mortality risk among hemodialysis patients receiving different vitamin D analogs","volume":"70","author":"Tentori","year":"2006","journal-title":"Kidney Int."},{"key":"10.1016\/j.mam.2008.04.001_bib180","doi-asserted-by":"crossref","first-page":"357","DOI":"10.1056\/NEJM199202063260601","article-title":"Treatment of postmenopausal osteoporosis with calcitriol or calcium","volume":"326","author":"Tilyard","year":"1992","journal-title":"New Engl. J. Med."},{"key":"10.1016\/j.mam.2008.04.001_bib181","doi-asserted-by":"crossref","first-page":"1478","DOI":"10.1124\/mol.59.6.1478","article-title":"Different molecular mechanisms of vitamin D(3) receptor antagonists","volume":"59","author":"Toell","year":"2001","journal-title":"Mol. Pharmacol."},{"key":"10.1016\/j.mam.2008.04.001_bib182","doi-asserted-by":"crossref","first-page":"142","DOI":"10.1007\/BF00296065","article-title":"A novel synthetic vitamin D analogue, 2 beta-(3-hydroxypropoxy)1 alpha, 25-dihydroxyvitamin D3 (ED-71), increases bone mass by stimulating the bone formation in normal and ovariectomized rats","volume":"54","author":"Tsurukami","year":"1994","journal-title":"Calcified Tissue Int."},{"key":"10.1016\/j.mam.2008.04.001_bib183","doi-asserted-by":"crossref","first-page":"4887","DOI":"10.1210\/en.2007-0267","article-title":"Vitamin D receptor-dependent inhibition of mammary tumor growth by EB1089 and ultraviolet radiation in vivo","volume":"148","author":"Valrance","year":"2007","journal-title":"Endocrinology"},{"key":"10.1016\/j.mam.2008.04.001_bib184","doi-asserted-by":"crossref","first-page":"223","DOI":"10.1002\/jcb.10329","article-title":"Analogs of 1alpha,25-dihydroxyvitamin D3 as pluripotent immunomodulators","volume":"88","author":"Van Etten","year":"2003","journal-title":"J. Cell. Biochem."},{"key":"10.1016\/j.mam.2008.04.001_bib185","doi-asserted-by":"crossref","first-page":"546","DOI":"10.1016\/j.jsbmb.2006.12.094","article-title":"Novel insights in the immune function of the vitamin D system: synergism with interferon-beta","volume":"103","author":"van Etten","year":"2007","journal-title":"J. Steroid Biochem. Mol. Biol."},{"key":"10.1016\/j.mam.2008.04.001_bib186","doi-asserted-by":"crossref","first-page":"93","DOI":"10.1016\/j.jsbmb.2005.06.002","article-title":"Immunoregulation by 1,25-dihydroxyvitamin D3: basic concepts","volume":"97","author":"van Etten","year":"2005","journal-title":"J. Steroid Biochem. Mol. Biol."},{"key":"10.1016\/j.mam.2008.04.001_bib187","doi-asserted-by":"crossref","first-page":"255","DOI":"10.1007\/s11060-007-9418-z","article-title":"1 alpha-Hydroxyvitamin D2 inhibits growth of human neuroblastoma","volume":"85","author":"van Ginkel","year":"2007","journal-title":"J. Neurooncol."},{"key":"10.1016\/j.mam.2008.04.001_bib188","doi-asserted-by":"crossref","first-page":"2103","DOI":"10.1210\/en.139.4.2102","article-title":"Apoptotic regression of MCF-7 xenografts in nude mice treated with the vitamin D analog, EB1089","volume":"139","author":"van Weelden","year":"1998","journal-title":"Endocrinology"},{"key":"10.1016\/j.mam.2008.04.001_bib189","doi-asserted-by":"crossref","first-page":"72","DOI":"10.1016\/0966-3274(93)90062-D","article-title":"Two novel vitamin D analogues, KH 1060 and CB 966, prolong skin allograft survival in mice","volume":"1","author":"Veyron","year":"1993","journal-title":"Transplant. Immunol."},{"key":"10.1016\/j.mam.2008.04.001_bib190","first-page":"3050","article-title":"1 alpha,25-Dihydroxy-16-ene-23-yne-26,27-hexafluorocholecalciferol, a noncalcemic analogue of 1 alpha,25-dihydroxyvitamin D3, inhibits azoxymethane-induced colonic tumorigenesis","volume":"55","author":"Wali","year":"1995","journal-title":"Cancer Res."},{"key":"10.1016\/j.mam.2008.04.001_bib191","doi-asserted-by":"crossref","first-page":"1483","DOI":"10.1002\/jbmr.5650081211","article-title":"Effect of 1,25,28-trihydroxyvitamin D2 and 1,24,25-trihydroxyvitamin D3 on intestinal calbindin-D9K mRNA and protein: is there a correlation with intestinal calcium transport?","volume":"8","author":"Wang","year":"1993","journal-title":"J. Bone Miner. Res."},{"key":"10.1016\/j.mam.2008.04.001_bib192","doi-asserted-by":"crossref","first-page":"629","DOI":"10.1016\/j.steroids.2004.05.015","article-title":"Toxicity and antineoplastic effect of (24R)-1,24-dihydroxyvitamin D3 (PRI-2191)","volume":"69","author":"Wietrzyk","year":"2004","journal-title":"Steroids"},{"key":"10.1016\/j.mam.2008.04.001_bib193","doi-asserted-by":"crossref","first-page":"90","DOI":"10.1124\/jpet.106.101261","article-title":"Role of phosphorus and vitamin D analogs in the pathogenesis of vascular calcification","volume":"318","author":"Wu-Wong","year":"2006","journal-title":"J. Pharmacol. Exp. Ther."},{"key":"10.1016\/j.mam.2008.04.001_bib194","doi-asserted-by":"crossref","first-page":"177","DOI":"10.1016\/j.jsbmb.2006.04.008","article-title":"Culture serum-induced conversion from agonist to antagonist of a Vitamin D analog, TEI-9647","volume":"100","author":"Yamaoka","year":"2006","journal-title":"J. Steroid Biochem. Mol. Biol."},{"key":"10.1016\/j.mam.2008.04.001_bib195","doi-asserted-by":"crossref","first-page":"S108","DOI":"10.1053\/ajkd.2003.50097","article-title":"Multicenter clinical trial of 22-oxa-1,25-dihydroxyvitamin D3 for chronic dialysis patients","volume":"41","author":"Yasuda","year":"2003","journal-title":"Am. J. Kidney Dis."},{"key":"10.1016\/j.mam.2008.04.001_bib196","doi-asserted-by":"crossref","first-page":"24","DOI":"10.1016\/0923-1811(94)90018-3","article-title":"Regulatory effects of 1,25-dihydroxyvitamin D3 and a novel vitamin D3 analogue MC903 on secretion of interleukin-1 alpha (IL-1 alpha) and IL-8 by normal human keratinocytes and a human squamous cell carcinoma cell line (HSC-1)","volume":"7","author":"Zhang","year":"1994","journal-title":"J. Dermatol. Sci."},{"key":"10.1016\/j.mam.2008.04.001_bib197","doi-asserted-by":"crossref","first-page":"323","DOI":"10.1158\/1078-0432.323.11.1","article-title":"Growth suppression of ovarian cancer xenografts in nude mice by vitamin D analogue EB1089","volume":"11","author":"Zhang","year":"2005","journal-title":"Clin. Cancer Res."},{"key":"10.1016\/j.mam.2008.04.001_bib198","doi-asserted-by":"crossref","first-page":"229","DOI":"10.2174\/156800906776842939","article-title":"Vitamin D receptor is a novel drug target for ovarian cancer treatment","volume":"6","author":"Zhang","year":"2006","journal-title":"Curr. Cancer Drug Targets"},{"key":"10.1016\/j.mam.2008.04.001_bib199","doi-asserted-by":"crossref","first-page":"197","DOI":"10.1016\/0960-0760(95)00256-1","article-title":"Enhancement of antiproliferative activity of 1alpha,25-dihydroxyvitamin D3 (analogs) by cytochrome P450 enzyme inhibitors is compound- and cell-type specific","volume":"57","author":"Zhao","year":"1996","journal-title":"J. Steroid Biochem. Mol. Biol."},{"key":"10.1016\/j.mam.2008.04.001_bib200","doi-asserted-by":"crossref","first-page":"3929","DOI":"10.1073\/pnas.87.10.3929","article-title":"1,25-Dihydroxy-16-ene-23-yne-vitamin D3 prolongs survival time of leukemic mice","volume":"87","author":"Zhou","year":"1990","journal-title":"Proc. Natl. Acad. Sci. U.S.A."},{"key":"10.1016\/j.mam.2008.04.001_bib201","doi-asserted-by":"crossref","first-page":"457","DOI":"10.1002\/jbmr.5650070414","article-title":"1,25-Dihydroxyvitamin D3 analog structure-function assessment of the rapid stimulation of intestinal calcium absorption (transcaltachia)","volume":"7","author":"Zhou","year":"1992","journal-title":"J. Bone Miner. Res."},{"key":"10.1016\/j.mam.2008.04.001_bib202","doi-asserted-by":"crossref","first-page":"591","DOI":"10.1159\/000089707","article-title":"Inhibition of parathyroid hormone: a dose equivalency study of paricalcitol and doxercalciferol","volume":"25","author":"Zisman","year":"2005","journal-title":"Am. J. Nephrol."}],"container-title":["Molecular Aspects of Medicine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0098299708000186?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0098299708000186?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2023,5,18]],"date-time":"2023-05-18T02:51:35Z","timestamp":1684378295000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0098299708000186"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2008,12]]},"references-count":203,"journal-issue":{"issue":"6","published-print":{"date-parts":[[2008,12]]}},"alternative-id":["S0098299708000186"],"URL":"https:\/\/doi.org\/10.1016\/j.mam.2008.04.001","relation":{},"ISSN":["0098-2997"],"issn-type":[{"value":"0098-2997","type":"print"}],"subject":[],"published":{"date-parts":[[2008,12]]}}}